Microneedle Transdermal Vaccine Delivery via Spray-Dried Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine delivery methods are invasive, painful, and require skilled professionals, and there is a need for more effective and patient-friendly routes for immunization, especially for cancers and infectious diseases, with existing vaccines facing challenges in stability, cost, and immune response consistency.
Innovation Solution
Development of microneedle-mediated transdermal delivery of microparticulate vaccines using spray-dried formulations containing whole cell lysates or proteins, combined with adjuvants like IL-2 and IL-12, to enhance immune response and stability, and exploration of alternative routes like buccal and oral delivery systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine delivery methods (injection) are used, then immune response is achieved, but the procedure is invasive, painful, and requires skilled professionals
Solution Approach 1:
The patent replaces the mechanical injection system with a microneedle array system that uses controlled mechanical insertion followed by dissolution or penetration to deliver vaccine antigens. The microneedles are designed to mechanically penetrate the stratum corneum and then deliver the antigen through dissolution in interstitial fluid or direct penetration, eliminating the need for syringes and trained personnel while maintaining immunogenicity.
Solution Approach 2:
The patent changes the physical parameters of the delivery system by using microneedles with specific dimensions (length, diameter, spacing) and material properties that enable painless penetration and controlled dissolution. The antigen formulation parameters are also optimized for stability and release kinetics from the microneedle matrix, transforming the delivery mechanism from injection to a controlled dissolution/penetration process.
2Stability of the object's composition
If vaccine stability is improved through formulation, then storage and shelf life are enhanced, but manufacturing complexity and cost increase
Solution Approach 1:
The patent employs composite material systems where vaccine antigens are formulated with stabilizing excipients, buffers, and protective agents within a microneedle matrix material. This composite approach enhances antigen stability during storage and delivery while the integrated microneedle structure simplifies the overall device compared to separate storage and delivery systems.
Solution Approach 2:
The microneedle array serves multiple functions: it acts as the delivery vehicle, the stabilizing matrix, and the application device itself. This multi-functionality reduces the number of separate components needed, simplifying manufacturing and reducing device complexity while maintaining enhanced vaccine stability through the formulated matrix.
3Ease of operation
If microneedle arrays are used for transdermal delivery, then pain and invasiveness are reduced, but delivery efficiency and immune response consistency may be affected
Solution Approach 1:
The patent applies local quality principles by designing microneedles with specific properties (sharpness, length, material composition) optimized for painless penetration of the stratum corneum, while the antigen formulation within each microneedle is locally optimized for consistent release kinetics and immunogenicity. The array geometry (spacing, density) is locally optimized to ensure uniform distribution and consistent immune response across the application site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microneedle-based transdermal delivery method induces significant immune responses with reduced pain and invasiveness, while the use of adjuvants and specific formulations enhances vaccine efficacy and stability, leading to effective tumor suppression and immune activation against various pathogens.
Implementation Method 1
The microneedle array is pressed against or inserted into the skin to penetrate the stratum corneum
Implementation Method 2
The microneedles are dissolved or penetrate the stratum corneum and deliver the vaccine antigen
Implementation Method 3
deliver the vaccine antigen through dissolution or penetration
Data Source
AI summary
A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.